Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PEMBROLIZUMAB Cause Skin hyperpigmentation? 18 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 18 reports of Skin hyperpigmentation have been filed in association with PEMBROLIZUMAB (KEYTRUDA). This represents 0.0% of all adverse event reports for PEMBROLIZUMAB.

18
Reports of Skin hyperpigmentation with PEMBROLIZUMAB
0.0%
of all PEMBROLIZUMAB reports
1
Deaths
8
Hospitalizations

How Dangerous Is Skin hyperpigmentation From PEMBROLIZUMAB?

Of the 18 reports, 1 (5.6%) resulted in death, 8 (44.4%) required hospitalization, and 3 (16.7%) were considered life-threatening.

Is Skin hyperpigmentation Listed in the Official Label?

Yes, Skin hyperpigmentation is listed as a known adverse reaction in the official FDA drug label for PEMBROLIZUMAB.

What Other Side Effects Does PEMBROLIZUMAB Cause?

Malignant neoplasm progression (10,111) Death (4,744) Diarrhoea (4,251) Fatigue (3,833) Off label use (3,416) Product use in unapproved indication (3,191) Pyrexia (3,155) Rash (2,900) Nausea (2,670) Decreased appetite (2,486)

What Other Drugs Cause Skin hyperpigmentation?

ADAPALENE (2,811) AVOBENZONE\OCTISALATE\OCTOCRYLENE (2,277) BIMATOPROST (189) AVOBENZONE\HOMOSALATE\OCTINOXATE\OCTISALATE\OXYBENZONE (182) DUPILUMAB (177) MINOCYCLINE (144) LENALIDOMIDE (142) METHOTREXATE (142) CAPECITABINE (136) COLLAGENASE CLOSTRIDIUM HISTOLYTICUM-AAES (120)

Which PEMBROLIZUMAB Alternatives Have Lower Skin hyperpigmentation Risk?

PEMBROLIZUMAB vs PEMETREXED PEMBROLIZUMAB vs PEMIGATINIB PEMBROLIZUMAB vs PENICILLAMINE PEMBROLIZUMAB vs PENICILLIN PEMBROLIZUMAB vs PENICILLIN G

Related Pages

PEMBROLIZUMAB Full Profile All Skin hyperpigmentation Reports All Drugs Causing Skin hyperpigmentation PEMBROLIZUMAB Demographics